Meeder Asset Management Inc Morphic Holding, Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$36.25 - $52.02 $688 - $988	-19 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$43.27 - $65.72 $129 - $197	-3 Reduced 13.64%	19 $1,000
Q2 2021 Aug 09, 2021	BUY	$45.13 - $64.99 $992 - $1,429	22 New	22 $1,000
Q4 2020 Feb 09, 2021	SELL	$25.66 - $34.55 $23,812 - $32,062	-928 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$12.65 - $29.57 $6,691 - $15,642	529 Added 132.58%	928 $26,000
Q1 2020 May 15, 2020	SELL	$10.84 - $20.85 $10,829 - $20,829	-999 Reduced 71.46%	399 $5,000
Q4 2019 Feb 13, 2020	BUY	$13.02 - $19.5 $9,608 - $14,391	738 Added 111.82%	1,398 $25,000
Q3 2019 Oct 17, 2019	BUY	$17.46 - $29.05 $11,523 - $19,173	660 New	660 $11,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.